Total submissions: 25
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV000048724 | SCV000076737 | pathogenic | Hereditary breast ovarian cancer syndrome | 2024-01-05 | criteria provided, single submitter | clinical testing | This sequence change falls in intron 15 of the BRCA1 gene. It does not directly change the encoded amino acid sequence of the BRCA1 protein. RNA analysis indicates that this variant induces altered splicing and may result in an absent or disrupted protein product. This variant is not present in population databases (gnomAD no frequency). This variant has been observed in individual(s) with breast and ovarian cancer (PMID: 10406662, 21120943, 21324516, 21965345, 24729269). This variant is also known as IVS16+6T>C. ClinVar contains an entry for this variant (Variation ID: 37620). Variants that disrupt the consensus splice site are a relatively common cause of aberrant splicing (PMID: 17576681, 9536098). Studies have shown that this variant results in activation of a cryptic splice donor site and introduces a premature termination codon (PMID: 10406662, 22505045). The resulting mRNA is expected to undergo nonsense-mediated decay. This variant disrupts the c.4986+6T nucleotide in the BRCA1 gene. Other variant(s) that disrupt this nucleotide have been determined to be pathogenic (PMID: 11179017, 16619214, 22160602). This suggests that this nucleotide is clinically significant, and that variants that disrupt this position are likely to be disease-causing. For these reasons, this variant has been classified as Pathogenic. |
Ambry Genetics | RCV000131837 | SCV000186892 | pathogenic | Hereditary cancer-predisposing syndrome | 2022-06-14 | criteria provided, single submitter | clinical testing | The c.4986+6T>C pathogenic mutation results from a T to C substitution 6 nucleotides after coding exon 14 in the BRCA1 gene. This alteration has been identified in multiple patients with early-onset breast cancer (Pal T et al. Cancer. 2015 Dec;121(23):4173-80; Biunno I et al. Fam. Cancer 2014 Sep;13(3):437-44; Rummel SK et al. Breast Cancer Res. Treat. 2017 Aug;164(3):593-601), as well as in ovarian cancer cohorts (Akbari MR et al. J. Med. Genet. 2011 Nov;48(11):783-6; Zhang S et al. Gynecol. Oncol. 2011 May;121(2):353-7). RNA splicing assays have shown that this mutation activates a cryptic splice donor site, resulting in an insertion, frameshift, and premature truncation (Scholl T et al. Am. J. Med. Genet. 1999; 85:113-6; Houdayer C. Hum. Mutat.. 2012 Aug; 33(8):1228-38; Ambry internal data). In addition, one study found that this nucleotide substitution is non-functional in a high throughput, genome editing, haploid cell survival assay (Findlay GM et al. Nature, 2018 10;562:217-222). Of note, this alteration is also designated as IVS16+6T>C in published literature. In silico splice site analysis predicts that this alteration will weaken the native splice donor site. Based on the available evidence, this alteration is classified as a pathogenic mutation. |
Gene |
RCV000159997 | SCV000210190 | pathogenic | not provided | 2022-05-27 | criteria provided, single submitter | clinical testing | Non-canonical splice site variant demonstrated to result in aberrant splicing and a truncated protein (Scholl 1999, Uchikawa 2007); Observed in multiple individuals with personal and/or family histories consistent with Hereditary Breast and Ovarian Cancer (Scholl 1999, Akbari 2011, Lynce 2015, Pal 2015, Rummel 2017); Published functional studies demonstrate a damaging effect: variant classified as non-functional based on a saturation genome editing (SGE) assay measuring cell survival (Findlay 2018); Not observed at a significant frequency in large population cohorts (gnomAD); In silico analysis supports a deleterious effect on splicing; Also known as 5105+6T>C and IVS16+6T>C; This variant is associated with the following publications: (PMID: 26913838, 21965345, 21324516, 23348723, 22505045, 10406662, 24729269, 23239986, 26250392, 26287763, 25782689, 23192404, 28727877, 28087643, 28503720, 30209399, 31159747, 33646313, 30787465, 17851636) |
CHEO Genetics Diagnostic Laboratory, |
RCV000735559 | SCV000219254 | pathogenic | Breast and/or ovarian cancer | 2017-03-03 | criteria provided, single submitter | clinical testing | |
Consortium of Investigators of Modifiers of BRCA1/2 |
RCV000031201 | SCV000326085 | pathogenic | Breast-ovarian cancer, familial, susceptibility to, 1 | 2015-10-02 | criteria provided, single submitter | clinical testing | |
Eurofins Ntd Llc |
RCV000159997 | SCV000484492 | likely pathogenic | not provided | 2015-07-24 | criteria provided, single submitter | clinical testing | |
Counsyl | RCV000031201 | SCV000677655 | likely pathogenic | Breast-ovarian cancer, familial, susceptibility to, 1 | 2017-04-01 | criteria provided, single submitter | clinical testing | |
Color Diagnostics, |
RCV000131837 | SCV000683231 | pathogenic | Hereditary cancer-predisposing syndrome | 2023-10-01 | criteria provided, single submitter | clinical testing | This variant causes a T>C nucleotide substitution at the +6 position of intron 15 of the BRCA1 gene. This variant is also known as IVS16+6T>C in the literature. RNA studies on carrier-derived RNA have found this variant to disrupt splicing in a manner that is expected to result in an absent or non-functional protein product (PMID: 10406662, 22505045). This variant has been reported to be loss-of-function in a haploid cell proliferation assay (PMID: 30209399). This variant has been reported in multiple individuals with personal and/or family history of breast and ovarian cancer (PMID: 10406662, 18703817, 21120943, 21324516, 24729269, 28503720). This variant has not been identified in the general population by the Genome Aggregation Database (gnomAD). Loss of BRCA1 function is a known mechanism of disease (clinicalgenome.org). Based on the available evidence, this variant is classified as Pathogenic. |
Gene |
RCV000159997 | SCV000693498 | likely pathogenic | not provided | 2020-01-01 | criteria provided, single submitter | clinical testing | This sequence change occurs 6 nucleotides after exon 16 of the BRCA1 gene. This position is conserved in the human genome and is crucial in mRNA processing. This mutation is expected to result in incorrect splicing, alteration in the reading frame and an absent or truncated protein. This variant is also known as IVS16+6T>C and has been reported in the international literature in patients with hereditary breast and ovarian cancer (PMID: 21324516, 21965345, 21120943). Experimental studies have shown that this sequence change creates an aberrant transcript by activating a cryptic splice donor site. Moreover, this prediction has been confirmed experimentally (PMID: 10406662, 22505045). The mutation database Clinvar contains entries for this variant (Variation ID:37620) In summary, this is a rare sequence change that is expected to affect the BRCA1 protein and cause disease. |
Women's Health and Genetics/Laboratory Corporation of America, |
RCV000048724 | SCV000699190 | pathogenic | Hereditary breast ovarian cancer syndrome | 2021-11-05 | criteria provided, single submitter | clinical testing | Variant summary: BRCA1 c.4986+6T>C alters a conserved nucleotide located close to a canonical splice site and therefore could affect mRNA splicing, leading to a significantly altered protein sequence. Several computational tools predict a significant impact on normal splicing: Two predict the variant abolishes the canonical 5' splicing donor site. One predict the variant weakens the canonical 5' splicing donor site. At least one publication reports experimental evidence that this variant affects mRNA splicing by using a cryptic site 65 nucleotides downstream of the canonical 5' splice donor site (Houdayer_2012). The variant was absent in 249776 control chromosomes. c.4986+6T>C has been reported in the literature in multiple individuals affected with Hereditary Breast And Ovarian Cancer Syndrome (example Rebbeck_2018). These data indicate that the variant is very likely to be associated with disease. At least one publication reports experimental evidence evaluating an impact on protein function (example, Findlay_2018). The most pronounced variant effect results in loss of HDR activity. Multiple clinical diagnostic laboratories have submitted clinical-significance assessments for this variant to ClinVar after 2014 without evidence for independent evaluation. All laboratories classified the variant as pathogenic/likely pathogenic. Based on the evidence outlined above, the variant was classified as pathogenic. |
Clinical Genetics DNA and cytogenetics Diagnostics Lab, |
RCV000031201 | SCV000744604 | pathogenic | Breast-ovarian cancer, familial, susceptibility to, 1 | 2015-09-21 | criteria provided, single submitter | clinical testing | |
Division of Medical Genetics, |
RCV000031201 | SCV001424820 | pathogenic | Breast-ovarian cancer, familial, susceptibility to, 1 | 2019-04-01 | criteria provided, single submitter | clinical testing | The c.5049+6T>C variant (also known as IVS16+6T>C) affects a cryptic splice donor site and leads to an aberrant transcript and truncated protein (Scholl 1999, Houdayer 2012). A different sequence change at the same position has also been shown to result in abnormal splicing (Chen 2006). The c.5049+6T>C variant has been reported in multiple individuals and families with breast and ovarian cancer (Scholl 1999, Zhang 2011, Akbari 2011, Caux-Moncoutier 2011, Biunno 2014). Thus, the c.5049+6T>C variant is interpreted as pathogenic. |
Laboratorio de Genetica e Diagnostico Molecular, |
RCV000031201 | SCV002512514 | likely pathogenic | Breast-ovarian cancer, familial, susceptibility to, 1 | 2022-01-05 | criteria provided, single submitter | clinical testing | ACMG classification criteria: PS3 supporting, PS4 moderate, PM2 moderate, PP1 supporting, PP3 supporting |
Sema4, |
RCV000131837 | SCV002537799 | pathogenic | Hereditary cancer-predisposing syndrome | 2021-05-06 | criteria provided, single submitter | curation | |
Baylor Genetics | RCV000031201 | SCV004215087 | pathogenic | Breast-ovarian cancer, familial, susceptibility to, 1 | 2024-03-29 | criteria provided, single submitter | clinical testing | |
Victorian Clinical Genetics Services, |
RCV000031201 | SCV005399610 | pathogenic | Breast-ovarian cancer, familial, susceptibility to, 1 | 2023-07-17 | criteria provided, single submitter | clinical testing | Based on the classification scheme VCGS_Germline_v1.3.4, this variant is classified as Pathogenic. Following criteria are met: 0102 - Loss of function is a known mechanism of disease in this gene and is associated with Fanconi anaemia, complementation group S (MIM#617883), susceptibility to breast and ovarian cancer (MIM#604370) and susceptibility to pancreatic cancer (MIM#614320). (I) 0108 - This gene is associated with both recessive and dominant disease. Susceptibility to breast and ovarian cancer follows an autosomal dominant inheritance pattern, while Fanconi anaemia is inherited in an autosomal recessive pattern (OMIM). (I) 0112 - The condition associated with this gene has incomplete penetrance. The highest estimate for cancer risk in carriers of pathogenic variants is 80% by the age of 70 years (PMID: 30551077). (I) 0251 - This variant is heterozygous. (I) 0209 - Splice site variant proven to affect splicing of the transcript with uncertain effect on protein sequence. Using semi-nested RT-PCR performed on total RNA isolated from patient peripheral blood cells, this variant was shown to result in a retention of a 69bp sequence in intron 15 which harbours at least one predicted STOP codon (PMID: 10406662). A subsequent study using a saturating genome editing assay demonstrated that this variant resulted in reduced mRNA expression and was functionally classified as a loss of function variant (PMID: 30209399). (SP) 0304 - Variant is present in gnomAD (v3) <0.01 for a condition (1 heterozygote, 0 homozygotes). (SP) 0311 - An alternative nucleotide change at the same non-canonical splice site is present in gnomAD (v2) at a frequency of 0.0000089 (1 heterozygote, 0 homozygotes). 0505 - Abnormal splicing is predicted by in silico tools and affected nucleotide is highly conserved. (SP) 0704 - Another non-canonical splice variant comparable to the one identified in this case has limited previous evidence for pathogenicity. The c.4986+6T>G non-canonical splice variant has been classified as 3 stars by an expert panel; however, it should be noted that the c.4986+6T>A non-canonical splice variant has been classified once as a VUS (ClinVar). (SP) 0801 - This variant has very strong previous evidence of pathogenicity in unrelated individuals. This variant has been classified as likely pathogenic or pathogenic by multiple clinical diagnostic laboratories (ClinVar) and has been reported in multiple individuals across different ethnicities (PMID: 29446198). (SP) 1208 - Inheritance information for this variant is not currently available in this individual. (I) Legend: (SP) - Supporting pathogenic, (I) - Information, (SB) - Supporting benign |
Quest Diagnostics Nichols Institute San Juan Capistrano | RCV000159997 | SCV005626124 | pathogenic | not provided | 2024-06-21 | criteria provided, single submitter | clinical testing | The BRCA1 c.4986+6T>C variant has been reported in the published literature in individuals and families with breast/ovarian cancer (PMIDs: 21120943 (2011), 21324516 (2011), 21965345 (2011), 24729269 (2014), 28503720 (2017), and 33646313 (2021)). In addition, RNA studies indicated that this variant activates a cryptic splice site and causes an inclusion of extra intronic sequences which encoded a truncated BRCA1 protein (PMIDs: 10406662 (1999), 22505045 (2012), and 23239986 (2012)). This variant has not been reported in large, multi-ethnic general populations (Genome Aggregation Database, http://gnomad.broadinstitute.org). Analysis of this variant using software algorithms for the prediction of the effect of nucleotide changes on splicing yielded predictions that this variant may affect proper BRCA1 mRNA splicing. Based on the available information, this variant is classified as pathogenic. |
Fulgent Genetics, |
RCV005016311 | SCV005647124 | pathogenic | Breast-ovarian cancer, familial, susceptibility to, 1; Pancreatic cancer, susceptibility to, 4; Fanconi anemia, complementation group S | 2024-04-21 | criteria provided, single submitter | clinical testing | |
Sharing Clinical Reports Project |
RCV000031201 | SCV000053801 | pathogenic | Breast-ovarian cancer, familial, susceptibility to, 1 | 2012-02-09 | no assertion criteria provided | clinical testing | |
Breast Cancer Information Core |
RCV000031201 | SCV000145238 | not provided | Breast-ovarian cancer, familial, susceptibility to, 1 | no assertion provided | clinical testing | ||
Research Molecular Genetics Laboratory, |
RCV000048724 | SCV000587440 | pathogenic | Hereditary breast ovarian cancer syndrome | 2014-01-31 | no assertion criteria provided | research | |
Diagnostic Laboratory, |
RCV000031201 | SCV000733602 | pathogenic | Breast-ovarian cancer, familial, susceptibility to, 1 | no assertion criteria provided | clinical testing | ||
Foulkes Cancer Genetics LDI, |
RCV000735559 | SCV000863697 | likely pathogenic | Breast and/or ovarian cancer | 2015-05-06 | no assertion criteria provided | clinical testing | |
Brotman Baty Institute, |
RCV000031201 | SCV001243880 | not provided | Breast-ovarian cancer, familial, susceptibility to, 1 | no assertion provided | in vitro | ||
Clinical Genetics Laboratory, |
RCV000159997 | SCV001906304 | pathogenic | not provided | no assertion criteria provided | clinical testing |